July 6th 2023
Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.
July 5th 2023
Expert perspectives on the appropriate selection and use of OFS in premenopausal patients with breast cancer.
Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the SOFT and TEXT clinical trials to elucidate combination treatment strategies with ovarian function suppression (OFS).
June 29th 2023
Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.
June 28th 2023
Comprehensive insight to available gonadotropin-releasing hormone (GnRH) agonists in breast cancer and the role they play when thinking about fertility preservation.
Key opinion leaders on breast cancer management provide a broad overview of fertility preservation strategies available to patients.
June 21st 2023
Focused discussion on the incidence of chemotherapy-induced menopause in patients receiving treatment for their breast cancer.
Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the subset of patients with breast cancer who are premenopausal and how that impacts their approach to disease management.
June 5th 2023
A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.
March 16th 2023
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
March 10th 2023
Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
March 9th 2023
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
March 7th 2023
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
March 2nd 2023
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
February 28th 2023
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
February 23rd 2023
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.